Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study

Introduction Denosumab is an effective antiresorptive molecule and reduces the risk of fracture in postmenopausal osteoporosis. Cessation of denosumab therapy however is associated with rapid declines in bone mineral density (BMD), rises in bone remodeling, and an increased risk of fracture. We eval...

Full description

Saved in:
Bibliographic Details
Published in:Endocrine 2023-06, Vol.80 (3), p.647-657
Main Authors: Khan, Aliya A., AbuAlrob, Hajar, M’Hiri, Iman, Ali, Dalal S., Dandurand, Karel, Said, Hosay, Alkassem, Hisham, Hakami, Yasser, Hweija, Ismail, Iqbal, Salman, Romanovschi, Mihai, Mehmood, Shehryar, Zariffeh, Heather, Guyatt, Gordon, Ibrahim, Quazi, Brignardello-Petersen, Romina, Syed, Hamza I.
Format: Article
Language:English
Subjects:
Bone Density
Bone Density Conservation Agents - pharmacology
Bone Density Conservation Agents - therapeutic use
Bone loss
Bone mineral density
Bone remodeling
Denosumab - pharmacology
Denosumab - therapeutic use
Diabetes
Endocrinology
Female
Fractures
Fractures, Bone - prevention & control
Hip
Humanities and Social Sciences
Humans
Internal Medicine
Medicine
Medicine & Public Health
multidisciplinary
Observational studies
Original
Original Article
Osteoporosis
Osteoporosis - drug therapy
Osteoporosis, Postmenopausal - drug therapy
Post-menopause
Postmenopause
Radius
Science
Spine (lumbar)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Denosumab is an effective antiresorptive molecule and reduces the risk of fracture in postmenopausal osteoporosis. Cessation of denosumab therapy however is associated with rapid declines in bone mineral density (BMD), rises in bone remodeling, and an increased risk of fracture. We evaluated the effect of low dose denosumab (30 mg every 6 months) on the prevention of bone loss following a switch from standard dose (60 mg of denosumab every 6 months) in a prospective observational study. Methods We recruited 114 women 50–90 years of age with postmenopausal osteoporosis at a moderate fracture risk without prior fragility fractures, who had been on denosumab 60 mg every 6 month. These women switched to low dose denosumab 30 mg every 6 months. Mean percentage change in lumbar spine (LS), femoral neck (FN), total hip (TH) and 1/3 distal radius (1/3RAD) BMD at 12 and 24 months were evaluated. Predictors for change in BMD were explored. Subgroup analysis for patients on denosumab 60 mg every 6 months for
ISSN:1559-0100
1355-008X
1559-0100
DOI:10.1007/s12020-022-03230-5